Skip to main content

Table 1 Characteristics of included patients at baseline

From: Male gender predicts mortality in a large cohort of patients receiving antiretroviral therapy in Uganda

Characteristics

Category

Total

Female

n (%)

Male

n (%)

p value

Age

14-19

333

233 (1.5)

100 (1.5)

< 0.001

 

20-29

3486

2866 (18.5)

620 (9.1)

 
 

30-39

9774

6966 (45)

2808 (41.2)

 
 

40-49

6292

4035 (26)

2257 (33.1)

 
 

50+

2430

1392 (9)

1038 (15.2)

 
 

Total (n)

22,315

15,492

6823

 

CD4

< 50

3452

2173 (16.9)

1279 (22.8)

< 0.001

 

50-99

2942

1944 (15.1)

998 (17.8)

 
 

100-149

3410

2391 (18.5)

1019 (18.2)

 
 

150-249

5740

4152 (32.2)

1588 (28.3)

 
 

250+

2954

2233 (17.3)

721 (12.9)

 
 

Total (n)

18,498

12,893

5605

 

WHO Stage at antiretroviral therapy initiation

Stage 1

465

339 (3.4)

126 (2.7)

< 0.001

 

Stage 2

7985

5615 (56)

2370 (51.2)

 
 

Stage 3

4982

3294 (32.9)

1688 (36.5)

 
 

Stage 4

1220

778 (7.8)

442 (9.6)

 
 

Total (n)

14,652

10,026

4626

 

TB at antiretroviral therapy initiation

No

21,207

14,847 (95.8)

6360 (93.2)

< 0.001

 

Yes

1108

645 (4.2)

463 (6.8)

 
 

Total (n)

22,315

15492

6823

 

Sexually transmitted infection diagnosed at antiretroviral therapy initiation

No

17,634

11,579 (74.7)

6055 (88.7)

< 0.001

 

Yes

4681

3913 (25.3)

768 (11.3)

 
 

Total (n)

22,315

15,492

6823

 

Switch from first antiretroviral therapy

No

20,675

14,313 (92.4)

6362 (93.2)

0.024

 

Yes

1640

1179 (7.6)

461 (6.8)

 
 

Total (n)

22,315

15,492

6823

 

Median months of follow-up time (interquartile range)

-

-

32 (20-47)

30 (18-39)

< 0.001